One of the fastest-growing segments of pharmaceuticals, as highlighted at the 2024 J.P. Morgan Healthcare Conference, is the antibody-drug conjugate (ADC) segment. ADCs consist of four main elements: ...

When a patient is diagnosed with a bacterial infection, medical staff need to identify the species attacking the body before it can be treated. The problem is, this process can take a few days and may ...

The market for HPAPIs is growing rapidly with the research industry's emphasis on oncology. The market is growing rapidly—probably the most aggressive growth rate that we see in the pharmaceutical ...

Lonza entered into two new collaborations with McSAF and Cristal Therapeutics to expand its bioconjugates offering. The collaborations are geared to enable the integration of two novel conjugation ...

Soon in virtually every hospital it will be possible to identify the bacterial species responsible for an infection developing in a patient in a matter of just a few minutes. A new, easy-to-adapt and ...

A technique developed by Miami University associate professors of chemistry and biochemistry Dominik Konkolewicz and Rick Page may help enable more rapid and efficient development of new materials for ...

Lonza today announced a long-term, strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct two new customer-dedicated ...

Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The extended relationship builds ...

This panel will present a focused playbook for biopharma patent practitioners allowing them to protect the full scope of innovation reflected in the biologic development process. The discussion will ...

We provide a detailed protocol for designing water-soluble CdSe–ZnS quantum dots (QDs) based on cap exchange of the native hydrophobic shell with dihydrolipoic acid (DHLA) ligands, and the preparation ...